Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830687 | 0.85 | ALOX15 (0.55) | ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7 | |
| SCHEMBL7334660 | 0.84 | ALOX15 (0.53) | ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7 | |
| SCHEMBL339492 | 0.83 | ALOX15 (0.81) | ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7 | |
| SCHEMBL13425276 | 0.82 | ALOX15 (0.61) | ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7 | |
| SCHEMBL9651946 | 0.82 | ALOX15 (0.52) | ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7 | |
| SCHEMBL8065531 | 0.80 | PLA2G4B (0.46) | — | |
| SCHEMBL9832704 | 0.80 | ALOX15 (0.63) | ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7 | |
| SCHEMBL2642068 | 0.80 | ALOX15 (0.63) | ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7 | |
| SCHEMBL166364 | 0.80 | ALOX15 (0.63) | ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7 | |
| SCHEMBL11210089 | 0.79 | ALOX15 (0.57) | ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1657235-B1 | Phenethanolamine-derived haptens, immunogens and conjugates comprising them and antibodies recognising said immunogenes and conjugates | RANDOX LAB LTD (GB) | 2011-09-21 | — | — | EP | disclosed |
| US-7192722-B2 | Phenethanolamine-derived haptens, immunogens, antibodies and conjugates | RANDOX LABORATORIES (GB) | 2007-03-20 | — | — | US | disclosed |
| US-20060223132-A1 | uses in competitive immunoassays for the detection of ractopamine, isoxsuprine and ritodrine | RANDOX LABORATORIES LIMITED (GB) | 2006-10-05 | — | — | US | disclosed |
| EP-1657235-A2 | Phenethanolamine-derived haptens, immunogens and conjugates comprising them and antibodies recognising said immunogenes and conjugates | Randox Laboratories Ltd. (GB) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223132-A1 | uses in competitive immunoassays for the detection of ractopamine, isoxsuprine and ritodrine | HRH3, HRH4, HRH1 | ALOX15 2626/4885ALDH1A1 464/4885SMN1; SMN2 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.